5WT9
Complex structure of PD-1 and nivolumab-Fab
Summary for 5WT9
Entry DOI | 10.2210/pdb5wt9/pdb |
Descriptor | Heavy Chain of Nivolumab, Light Chain of Nivolumab, Programmed cell death protein 1, ... (5 entities in total) |
Functional Keywords | pd-1, nivolumab, immune system |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 3 |
Total formula weight | 67537.26 |
Authors | |
Primary citation | Tan, S.,Zhang, H.,Chai, Y.,Song, H.,Tong, Z.,Wang, Q.,Qi, J.,Wong, G.,Zhu, X.,Liu, W.J.,Gao, S.,Wang, Z.,Shi, Y.,Yang, F.,Gao, G.F.,Yan, J. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun, 8:14369-14369, 2017 Cited by PubMed Abstract: Cancer immunotherapy by targeting of immune checkpoint molecules has been a research 'hot-spot' in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically since 2014. However, the binding mechanism of nivolumab to PD-1 has not yet been shown, despite a recent report describing the complex structure of pembrolizumab/PD-1. It has previously been speculated that PD-1 glycosylation is involved in nivolumab recognition. Here we report the complex structure of nivolumab with PD-1 and evaluate the effects of PD-1 N-glycosylation on the interactions with nivolumab. Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. Nivolumab binds to a completely different area than pembrolizumab. These results provide the basis for the design of future inhibitory molecules targeting PD-1. PubMed: 28165004DOI: 10.1038/ncomms14369 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.401 Å) |
Structure validation
Download full validation report